Therapy Detail

Therapy Name CPI-0610
Synonym
Therapy Description

CPI-0610 is a small molecule that binds to BET bromodomains and inhibits interaction with acetylated histones, resulting in regulation of BET-dependent gene expression and anti-tumor effects (PMID: 26815195).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
CPI-0610 BET Inhibitor (Pan) 25 CPI-0610 is a small molecule that binds to BET bromodomains and inhibits interaction with acetylated histones, resulting in regulation of BET-dependent gene expression and anti-tumor effects (PMID: 26815195).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown follicular lymphoma not applicable CPI-0610 Phase I Actionable In a Phase I trial, treatment with CPI-0610 resulted in a partial response in one patient with follicular lymphoma (Blood 2015 126:1491). detail...
Unknown unknown diffuse large B-cell lymphoma not applicable CPI-0610 Phase I Actionable In a Phase I trial, treatment with CPI-0610 resulted in a complete response in two patients with diffuse large B-cell lymphoma (Blood 2015 126:1491). detail...
Unknown unknown lymphoma not applicable CPI-0610 Phase I Actionable In a Phase I trial, treatment with CPI-0610 in lymphoma patients resulted in decreased tumor volume in five patients and stable disease in six patients (Blood 2015 126:1491). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02986919 Phase II CPI-0610 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Withdrawn
NCT01949883 Phase I CPI-0610 A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma Active, not recruiting
NCT02158858 Phase I CPI-0610 A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms Recruiting
NCT02157636 Phase I CPI-0610 A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma Completed